WYE-125132 ≥98%, crystalline solid
Leverantör: Cayman Chemical
Synonyms:
1-(4-(4-(8-Oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)-3-methylurea, WYE-132
WYE-125132 is an ATP-competitive inhibitor of mTOR (IC50 = 0,19 nM) that inhibits signaling through both mTORC1 and mTORC2. It is selective for mTOR over phosphatidylinositol 3-kinase isoforms. WYE-125132 is effective against mTORC1 and mTORC2 in diverse cancer models, both in vitro and in vivo. Oral administration of WYE-125132 alone blocks mTOR signaling and prevents tumor growth in breast, lung, renal, and glioma cancer xenografts in mice, while combination therapy with the VEGF-inhibitor bevacizumab causes complete regression of A498 renal carcinoma tumors. In addition to its applications in cancer, WYE-125132 has been used to delineate novel aspects of mTOR signaling.
MW:
519,6 g/mol |
MDL Number:
MFCD22420813 CAS nummer: 1144068-46-1 |
Learn more
About VWR
Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...